TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29244528
Drug: Lapatinib (LAP)
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lapatinib (LAP) + Trastuzumab (TRAS) + Aromatase Inhibitor (AI)
Study: 29244528
Drug: Lapatinib (LAP)
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lapatinib (LAP) + Aromatase Inhibitor (AI)
Study: 29244528
Drug: Trastuzumab (TRAS)
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab (TRAS) + Aromatase Inhibitor (AI)
Study: 28479001
Drug: Acetaminophen 1000
Normalized name: acetaminophen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1000 mg 3 times a day
Study: 28479001
Drug: Ibuprofen 600
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg 3 times a day
Study: 26630680
Drug: 5‐methylenetetrahydrofolate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐methylenetetrahydrofolate (1 mg daily)
Study: 30283911
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (1 mg daily)
Study: 17159119
Drug: Apraxia treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apraxia treatment
Study: 17159119
Drug: Control (aphasia)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (aphasia) treatment
Study: 15504842
Drug: Indinavir/ritonavir (IDV/RTV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir/ritonavir (IDV/RTV) at 667/100 mg every 12 hours
Study: 15504842
Drug: Indinavir (IDV)
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indinavir (IDV) alone at 800 mg every 8 hours
Study: 11174287
Drug: Intraluminal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraluminal administration of peppermint oil (200 mL solution: 8 mL peppermint oil + 0.2 mL Tween 80 per 1 L water with 0.04% indigo carmine)
Study: 11174287
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (solution without peppermint oil)
Study: 9430090
Drug: Dietary sitosterol
Normalized name: sitosterols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary sitosterol intake increased to 1.8 mg/kg, 2.6 mg/kg, and 3.5 mg/kg/day in the homozygote after a basal low-sitosterol diet (33 mg per 2000 kcal).
Study: 30264119
Drug: Algorithm-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm-based therapy (n=255)
Study: 22572889
Drug: Lu AA21004
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AA21004 5 mg/day
Study: 20942269
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine administration (combined with intrathecal bupivacaine)
Study: 21784372
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg plus ezetimibe 10 mg
Study: 16140027
Drug: Inhaled bimosiamose
Normalized name: Bimosiamose
DrugBank: Bimosiamose (DB06197)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled bimosiamose 70 mg bid on days 1-3 and 70 mg once on the morning of day 4
Study: 10444051
Drug: High oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High oxygen transmissibility (Dk/L) RGP lenses for 12 months of extended wear
Study: 10444051
Drug: Reasons for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reasons for failure to adapt to RGP daily wear
Study: 2801572
Drug: Nicardipine 2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 2.5, 5.0, and 10.0 mg intravenous
Study: 4271320
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with immunotherapy (multiple weekly intradermal injections of irradiated stored AML cells and Glaxo B.C.G.)
Study: 31754882
Drug: Dotinurad 4
Normalized name: Dotinurad
DrugBank: Dotinurad (DB16145)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Dotinurad 4 mg
Study: 28287476
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice containing 409 mg total (poly)phenols
Study: 28287476
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice containing 787 mg total (poly)phenols
Study: 28287476
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice containing 1238 mg total (poly)phenols
Study: 28287476
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice containing 1534 mg total (poly)phenols
Study: 28287476
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice containing 1910 mg total (poly)phenols
Study: 28287476
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice (all doses)
Study: 25249405
Drug: Weight, waist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight, waist or hip circumferences, insulin levels, high triglycerides (TG), low high-density lipoprotein (HDL)
Study: 23711600
Drug: IV-PCA morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV-PCA morphine plus intra- and postoperative ketamine and clonidine premedication (MCK)
Study: 23711600
Drug: IV-PCA morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV-PCA morphine alone (M)
Study: 23711600
Drug: IV-PCA morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV-PCA morphine plus oral clonidine premedication (MC)
Study: 23711600
Drug: IV-PCA morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV-PCA morphine plus intra- and postoperative ketamine (MK)
Study: 19572992
Drug: Parenteral ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral ampicillin (P‐Ab)
Study: 19572992
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin (O‐Ab)
Study: 19572992
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic (N‐Ab)
Study: 1164639
Drug: Clobetasone butyrate
Normalized name: clobetasone butyrate
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Clobetasone butyrate 0.05% ointment
Study: 11479164
Drug: Short daily
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short daily hemodialysis (DHD)
Study: 8001208
Drug: mivacurium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: mivacurium 0.15 mg.kg‐1 as a single bolus dose
Study: 8001208
Drug: mivacurium 0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: mivacurium 0.015 mg.kg‐1 followed by mivacurium 0.135 mg.kg‐1
Study: 8001208
Drug: rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium 0.6 mg.kg‐1 as a single bolus dose
Study: 8001208
Drug: rocuronium 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium 0.06 mg.kg‐1 followed by rocuronium 0.54 mg.kg‐1
Study: 8001208
Drug: mivacurium 0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: mivacurium 0.015 mg.kg‐1 followed by rocuronium 0.54 mg.kg‐1
Study: 8001208
Drug: rocuronium 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium 0.06 mg.kg‐1 followed by mivacurium 0.135 mg.kg‐1
Study: 8001208
Drug: succinylcholine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: succinylcholine 1.0 mg.kg‐1
Study: 25876346
Drug: Scalp acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalp acupuncture and EEG biofeedback therapy (combined therapy)
Study: 25876346
Drug: EEG biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: EEG biofeedback therapy (control group)
Study: 21750460
Drug: Botox injection
Normalized name: Botox
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botox injection
Study: 21750460
Drug: Lidocaine/Depomedrol injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/Depomedrol injection
Study: 20010618
Drug: valsartan/HCTZ 160/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan/HCTZ 160/12.5 mg (V/HCTZ)
Study: 20010618
Drug: valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 80 mg (V-low)
Study: 20010618
Drug: valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 160 mg (V-high)
Study: 31529406
Drug: Atacicept (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atacicept (all doses)
Study: 30481790
Drug: Ophthalmic insert
Normalized name: OPHTHALMIC INSERT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic insert Mydriasert®
Study: 24437167
Drug: Sublingual dose
Normalized name: Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual dose of nitrates (nitroglycerin and mononitrate isosorbide)
Study: 19633827
Drug: Blood pressure
Normalized name: Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure lowering treatment with perindopril-indapamide (n = 623)
Study: 11303848
Drug: Cefepime 50
Normalized name: cefepime 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 50 mg/kg/dose administered every 8 to 12 hours
Study: 11303848
Drug: Ceftazidime, Cefotaxime,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime, Cefotaxime, Cefuroxime (comparator therapy)
Study: 8491068
Drug: Remikiren (intravenous)
Normalized name: remikiren
DrugBank: Remikiren (DB00212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remikiren (intravenous) at doses of 10, 20, 40, 80, 160, and 320 mg
Study: 8491068
Drug: Remikiren (oral)
Normalized name: remikiren
DrugBank: Remikiren (DB00212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remikiren (oral) at doses of 100, 200, 400, 800, and 1600 mg
Study: 8491068
Drug: Remikiren (oral)
Normalized name: remikiren
DrugBank: Remikiren (DB00212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remikiren (oral) at 1600 mg
Study: 3329766
Drug: Choline magnesium
Normalized name: Choline Magnesium Trisalicylate
DrugBank: Choline (DB00122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Choline magnesium trisalicylate (CMT) 655 mg
Study: 3329766
Drug: Acetyl salicylic
Normalized name: Acetyl salicylic acid specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl salicylic acid (ASA) 652 mg
Study: 26684923
Drug: Ultra-low-dose buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose buprenorphine (initial dosage 0.1 mg once or twice daily; mean final dosage 0.44 mg/day)
Study: 24441865
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing (OD) of amikacin (15 or 20 mg/kg)
Study: 24441865
Drug: Twice-daily dosing
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily dosing (TD) of amikacin (15 or 20 mg/kg)
Study: 24441865
Drug: Amikacin pharmacokinetics
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin pharmacokinetics
Study: 24441865
Drug: Amikacin dosing
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin dosing based on neonatal age
Study: 22251022
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to an alternate antidepressant (venlafaxine)
Study: 22251022
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to an alternate SSRI plus cognitive behavior therapy (CBT)
Study: 18534618
Drug: Inhaled CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled CO2 (0.8%) for 2 hours
Study: 15668285
Drug: Weekly irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly irinotecan at a dose of 70 mg/m(2) days 1, 8, 15, 22, 29 in combination with capecitabine 1000 mg/m(2) twice daily days 1-14 and days 22-35 every 6 weeks (arm A)
Study: 15668285
Drug: 3-weekly irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-weekly irinotecan at a dose of 300/240 mg/m(2) day 1 and days 22 in combination with capecitabine 1000 mg/m(2) twice daily days 1-14 and days 22-35 every 6 weeks (arm B)
Study: 2873010
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg lormetazepam
Study: 7785682
Drug: Topical 0.125%
Normalized name: sodium hypochlorite topical 0.125% topical spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.125% verapamil
Study: 7785682
Drug: Topical 0.25%
Normalized name: permethrin topical 0.25% topical kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.25% verapamil
Study: 25076
Drug: Flunitrazepam 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 0.01 mg kg‐1
Study: 25076
Drug: Flunitrazepam 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 0.02 mg kg‐1
Study: 25076
Drug: Diazepam 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.125 mg kg‐1
Study: 25076
Drug: Flunitrazepam double
Normalized name: flunitrazepam
DrugBank: Flunitrazepam (DB01544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam double dose
Study: 25076
Drug: Flunitrazepam larger
Normalized name: flunitrazepam
DrugBank: Flunitrazepam (DB01544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam larger doses
Study: 25076
Drug: Diazepam larger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam larger doses
Study: 27900446
Drug: Obinutuzumab plus
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab plus bendamustine (G-B)
Study: 23271192
Drug: Aripiprazole 2
Normalized name: aripiprazole 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 2 mg
Study: 23271192
Drug: Aripiprazole 5
Normalized name: aripiprazole 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 5 mg
Study: 18261195
Drug: Aripiprazole 10
Normalized name: aripiprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 10 mg
Study: 23271192
Drug: Aripiprazole 30
Normalized name: aripiprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 30 mg
Study: 19797985
Drug: Aripiprazole (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (all doses)
Study: 20957705
Drug: Orlistat with
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat with cognitive‐behavioral therapy, guided‐self‐help (CBTgsh)
Study: 19609438
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) as regular therapy
Study: 15133343
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (three times every 3 hours)
Study: 11358560
Drug: Ointment base
Normalized name: Ointment base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment base alone
Study: 8024677
Drug: Mecamylamine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine (various doses)
Study: 22371898
Drug: Lersivirine (LRV)
Normalized name: ethanol
DrugBank: Lersivirine (DB11649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lersivirine (LRV) 2,400 mg
Study: 17355729
Drug: Verteporfin photodynamic
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin photodynamic therapy combined with anti-angiogenic agents (ranibizumab or pegaptanib)
Study: 17355729
Drug: Anti-angiogenic agents
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-angiogenic agents (ranibizumab or pegaptanib)
Study: 19948277
Drug: Verteporfin photodynamic
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin photodynamic therapy
Study: 17355729
Drug: Anti-angiogenic agents
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-angiogenic agents
Study: 16222916
Drug: Water fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water fortified with 10 mg elemental iron and 100 mg ascorbic acid per liter
Study: 16222916
Drug: Water containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water containing only 100 mg ascorbic acid per liter
Study: 7484997
Drug: Mesalazine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine (1.5 g/day) for 12 weeks after surgery
Study: 2049250
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein meal (10.5 g of protein)
Study: 2049250
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein meal (30.5 g of protein)
Study: 7451775
Drug: Venom skin
Normalized name: MENTHA PIPERITA LEAF 10 g in 100 g / APIS MELLIFERA VENOM 30 g in 100 g / TOCOPHEROL 15 g in 100 g TOPICAL CREAM [HOUKEA Bee Venom Skin Cream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venom skin testing at concentrations of 1 microgram/ml or less
Study: 6299612
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (Propranolol and Atenolol)
Study: 29478874
Drug: Memory-Focused Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memory-Focused Cognitive Therapy (MFCT) sessions (5×120min in 1 week)
Study: 29478874
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (ongoing treatment-as-usual; TAU)
Study: 24568566
Drug: Male who
Normalized name: EQUISETUM HYEMALE WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Male who used a stimulant to study
Study: 24568566
Drug: Nonmedical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonmedical use of prescription stimulants (NMUPS) as a study aid
Study: 17363405
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl PCA
Study: 12592266
Drug: Control (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (after treatment)
Study: 7041831
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg levamisole
Study: 7041831
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg levamisole
Study: 7041831
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg levamisole (classical dosage schedule)
Study: 28321001
Drug: ARB/CCB combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB/CCB combination therapy (irbesartan 100 mg + amlodipine 5 mg)
Study: 28321001
Drug: ARB/diuretic combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB/diuretic combination (daily irbesartan 100 mg + trichlormethiazide 1 mg)
Study: 26445302
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) administered orally for 48 hours before and 24 hours after coronary angiography
Study: 23644107
Drug: Syndrome differentiation-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syndrome differentiation-based treatment with traditional Chinese medicine (TCM)
Study: 23644107
Drug: Oral losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral losartan therapy (50 mg/day)
Study: 19428297
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of casopitant mesylate (150 mg)
Study: 19428297
Drug: 3-day intravenous
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day intravenous plus oral casopitant mesylate (90 mg intravenous on day 1 plus 50 mg oral on days 2 and 3)
Study: 17021784
Drug: Ear drops
Normalized name: Ear Drops
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ear drops containing antibiotic and corticosteroid (Control)
Study: 10524688
Drug: Weekly MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly MTX
Study: 1937373
Drug: 50% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% glucose in water (G/W)
Study: 1937373
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (N/S)
Study: 6129185
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + cyclic SRIF (100 micrograms/hr i.v.) for ten hours
Study: 6129185
Drug: Insulin alone
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin alone (10 units as a bolus + infusion 1 U/hr)
Study: 20437554
Drug: GKI infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GKI infusion
Study: 18768029
Drug: Dental hygiene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental hygiene activities including prophylaxis, sealants application, topical fluoride, fluoride mouthrinses, and tooth brushing instructional activity.
Study: 15842138
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western medical treatment (Control)
Study: 12578487
Drug: Acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine (600 mg twice per day)
Study: 8776276
Drug: Isradipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (5 mg 3 times daily)
Study: 15797966
Drug: DHEA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (50 mg/d, 16 wk)
Study: 10326324
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose cyclosporin A
Study: 10326324
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cyclosporin A
Study: 8567042
Drug: Remikiren (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remikiren (600 mg, single oral dose) during high sodium period
Study: 3554643
Drug: Cyclosporine (15‐17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (15‐17 mg/kg/day)
Study: 3554643
Drug: Cyclosporine (15‐17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (15‐17 mg/kg/day) + Prednisolone (0.3 mg/kg/day)
Study: 27177100
Drug: Heart‐Gallbladder acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart‐Gallbladder acupuncture treatment
Study: 23286297
Drug: Conventional acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional acupuncture treatment
Study: 22925832
Drug: Exercise (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise (both doses)
Study: 9474071
Drug: Discontinuing hospital-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuing hospital-based treatment within 24 hours without achieving a peak expiratory flow rate of at least 50% of predicted
Study: 2544254
Drug: Peripheral parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral parenteral nutrition (PPN) plus enteral nutrition (EN)
Study: 31659803
Drug: GB001 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: GB001 (30 mg) once daily for 28 days